Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.stem.2015.03.011 http://scihub22266oqcxt.onion/10.1016/j.stem.2015.03.011 C5611846!5611846!25842976     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Stem+Cell 2015 ; 16 (4): 357-66 Nephropedia Template TP {{tp|p=25842976|t=2015. New Cell Sources for T Cell Engineering and Adoptive Immunotherapy |pdf=|usr=}}{{25842976}} gab.com Text New Cell Sources for T Cell Engineering and Adoptive Immunotherapy JO: Cell Stem Cell http://www.kidney.de/pget.php?&tw=1&pmid=25842976 #FOAvip The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products. Twit Text FOAVip New Cell Sources for T Cell Engineering and Adoptive Immunotherapy ????Cell Stem Cell http://www.kidney.de/pget.php?&tw=1&pmid=25842976 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25842976 #FOAvip English Wikipedia <ref>{{Cite pmid|25842976}}</ref> New Cell Sources for T Cell Engineering and Adoptive Immunotherapy #MMPMID25842976 Themeli M; Rivière I; Sadelain M Cell Stem Cell 2015[Apr]; 16 (4): 357-66 PMID25842976show ga The promising clinical results obtained with engineered T cells, including chimeric antigen receptor (CAR) therapy, call for further advancements to facilitate and broaden their applicability. One potentially beneficial innovation is to exploit new T cell sources that reduce the need for autologous cell manufacturing and enable cell transfer across histocompatibility barriers. Here we review emerging T cell engineering approaches that utilize alternative T cell sources, which include virus-specific or T cell receptor-less allogeneic T cells, expanded lymphoid progenitors, and induced pluripotent stem cell (iPSC)-derived T lymphocytes. The latter offer the prospect for true off-the-shelf, genetically enhanced, histocompatible cell therapy products. äNew Cell Sources for T Cell Engineering and Adoptive Immunotherapy (epmc).pdf DeepDyve Pubget Overpricing